De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor
Yuchen Xu,Rui Song,Riley E. Perszyk,Wenjuan Chen,Sukhan Kim,Kristen L. Park,James P. Allen,Kelsey A. Nocilla,Jing Zhang,Wenshu XiangWei,Anel Tankovic,Ellington D. McDaniels,Rehan Sheikh,Ruth K. Mizu,Manish M. Karamchandani,Chun Hu,Hirofumi Kusumoto,Joseph Pecha,Gerarda Cappuccio,John Gaitanis,Jennifer Sullivan,Vandana Shashi,Slave Petrovski,Robin-Tobias Jauss,Hyun Kyung Lee,Xiuhua Bozarth,David R. Lynch,Ingo Helbig,Tyler Mark Pierson,Cornelius F. Boerkoel,Scott J. Myers,Johannes R. Lemke,Timothy A. Benke,Hongjie Yuan,Stephen F. Traynelis
DOI: https://doi.org/10.1007/s00018-023-05069-z
IF: 8
2024-03-29
Cellular and Molecular Life Sciences
Abstract:N-methyl- d -aspartate receptors (NMDARs) are members of the glutamate receptor family and participate in excitatory postsynaptic transmission throughout the central nervous system. Genetic variants in GRIN genes encoding NMDAR subunits are associated with a spectrum of neurological disorders. The M3 transmembrane helices of the NMDAR couple directly to the agonist-binding domains and form a helical bundle crossing in the closed receptors that occludes the pore. The M3 functions as a transduction element whose conformational change couples ligand binding to opening of an ion conducting pore. In this study, we report the functional consequences of 48 de novo missense variants in GRIN1 , GRIN2A , and GRIN2B that alter residues in the M3 transmembrane helix. These de novo variants were identified in children with neurological and neuropsychiatric disorders including epilepsy, developmental delay, intellectual disability, hypotonia and attention deficit hyperactivity disorder. All 48 variants in M3 for which comprehensive testing was completed produce a gain-of-function (28/48) compared to loss-of-function (9/48); 11 variants had an indeterminant phenotype. This supports the idea that a key structural feature of the M3 gate exists to stabilize the closed state so that agonist binding can drive channel opening. Given that most M3 variants enhance channel gating, we assessed the potency of FDA-approved NMDAR channel blockers on these variant receptors. These data provide new insight into the structure–function relationship of the NMDAR gate, and suggest that variants within the M3 transmembrane helix produce a gain-of-function.
cell biology,biochemistry & molecular biology